Sutent, Immunotherapy Combo Significantly Reduces Tumor Growth in HCC Mouse Model – Immuno-Oncology News
Immuno-Oncology News |
Sutent, Immunotherapy Combo Significantly Reduces Tumor Growth in HCC Mouse Model
Immuno-Oncology News Combining the chemotherapy agent Sutent (sunitinib) with immune checkpoint inhibitors that boost the immune system may help patients with hepatocellular carcinoma (HCC), the most common form of liver cancer. Preclinical data in HCC mice models shows … |
